Ganglioside-based vaccines and anti-idiotype antibodies for active immunotherapy against cancer

Expert Review of Vaccines

Volumn 2, Issue 6, 2003, Pages 817-823

  Fernández, Luis E ^a   Alonso, Daniel F ^a   Gomez, Daniel E ^b   Vázquez, Ana M ^b  

^a CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

^b UNIVERSIDAD NACIONAL DE QUILMES   (Argentina)

Author keywords

Adjuvant therapy; Anti idiotype; Breast cancer; Ganglioside; Lung cancer; Melanoma; Neoantigens; Residual disease; Vaccine

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; CANVAXIN; GANGLIOSIDE; GANGLIOSIDE GD2; GANGLIOSIDE GD3; GANGLIOSIDE GM2; GANGLIOSIDE GM3; IMMUNOGLOBULIN G ANTIBODY; MELANOMA VACCINE; MONOCLONAL ANTIBODY; N ACETYLNEURAMINIC ACID; N GLYCOLOYLNEURAMINIC ACID; VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; BREAST CANCER; CANCER IMMUNOTHERAPY; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; LUNG CANCER; MACACA; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEOLIPOSOME; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; VACCINE PRODUCTION;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; CANCER VACCINES; CLINICAL TRIALS; GANGLIOSIDES; HUMANS; NEOPLASMS; VACCINES;

EID: 0346849720     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.2.6.817     Document Type: Review

References (54)

1. Pardoll DM. Inducing autoimmune disease to treat cancer. Natl Acad. Sci. USA 96, 5340-5342 (1999).
2. Montero E, Amador JF, Perez R, Lage A. Tumor-specific immunotherapy based on dominant models of natural tolerance. Med. Hypotheses 54, 531-536 (2000).
3. Marincola FM, Wang E, Herlyn M et al. Tumors as elusive targets of T-cell-based active immunotherapy. Trends Immunol. 24, 334-341 (2003).
4. Dunn GP, Bruce AT, Ikeda H et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3, 991-998 (2002).
5. Cunto-Amesty G, Monzavi-Karbassi B, Luo P, Jousheghany F, Kieber-Emmons T. Strategies in cancer vaccines development. Int. J. Parasitol. 33, 597-613 (2003).
6. Kadison AS, Morton DL. Immunotherapy of malignant melanoma. Surg. Clin. North Am. 83, 343-370 (2003).
7. Smith B, Selby P, Southgate J et al. Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 338, 1227-1229 (1991).
8. Sabbatini R, Federico M, Morselli M et al. Detection of circulating tumor cells by reverse transcriptase polymerase chain reaction of maspin in patients with breast cancer undergoing conventional-dose chemotherapy. J. Clin. Oncol. 18, 1914-1920 (2000).
9. Xu D, Gruber A, Peterson C, Pisa P. Telomerase activity and expression of telomerase components in acute myelogenous leukemia. Br. J. Haematol. 102, 1367-1375 (1998).
10. Soria JC, Gauthier LR, Raymond et al. Molecular detection of telomerase-positive circulating epithelial cells in metastatic breast cancer patients. Clin. Cancer Res. 5, 971-975 (1999).
11. Sapi E, Okpokwasili M, Rutherford T. Detection of telomerase-positive circulating epithelial cells in ovarian cancer patients. Cancer Detect. Prev. 26, 158-167 (2002).
12. Gogas H, Kefala G, Bafaloukos D et al. Prognostic significance of the sequential detection of circulating melanoma cells by RT-PCR in high-risk melanoma patients receiving adjuvant interferon. Br. J. Cancer 87, 181-186 (2002).
13. Irie RF, Irie K, Morton DL. A membrane antigen common to human cancer and fetal brain tissues. Cancer Res. 36, 3510-3517 (1976).
14. Cahan LD, Irie RF, Singh R et al. Identification of human neuroectodermal tumor antigen (OFA-I-2) as ganglioside GD2. Proc. Natl Acad. Sci. USA 79, 7629-7633 (1982).
15. Tai T, Paulson JC, Cahan LD et al. Ganglioside GM2 as a human tumor antigen (OFA-I-1). Proc. Natl Acad. Sci. USA 80, 5392-5396 (1983).
16. Houghton AN, Mintzer D, Cordon-Cardo C et al. Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a Phase I trial in patients with malignant melanoma. Natl. Acad. Sci. USA 82, 1242-1246 (1985).
17. Cheung NK, Medof ME and Munn D. Immunotherapy with GD2 specific monoclonal antibodies. Prog. Clin. Biol. Res. 271, 619-632 (1988).
18. Irie RF, Matsuki T and Morton DL. Human monocloanl antidody to ganglioside GM2 for melanoma treatment. Lancet 1, 786-787 (1989).
19. Jones PC, Sze LL, Liu PY, Morton DL, Irie RF. Prolonged survival for melanoma patients with elevated IgM antibodies to oncofetal antigen. J. Natl. Cancer Inst. 66, 249-254 (1981).
20. Livingston PO. Approaches to augmenting the immunogenicity of melanoma gangliosides: from whole melanoma cells to ganglioside-KLH conjugate vaccines. Immunol. Rev. 145, 147-166 (1995).
21. Livingston PO, Zhang S, Lloyd KO. Carbohydrate vaccines that induce antibodies against cancer. 1. Rationale. Cancer Immunol. Immunother. 45, 1-9 (1997).
22. Garofalo T, Sorice M, Misasi R et al. A novel mechanism of CD4 down-modulation induced by monosialoganglioside GM3. J. Biol. Chem. 273, 35153-35160 (1998).
23. Kanda N. Gangliosides GD1a and GM3 induce interleukin-10 production by human T-cells. Biochem. Biophys. Res. Comm. 256, 41-44 (1999).
24. Takahashi K, Ono K, Hirabayashi Y et al. Escape mechanisms of melanoma from immune system by soluble melanoma antigens. J. Immunol. 140, 3244-3248 (1988).
25. Portoukalian J. Immunoregulatory activity of gangliosides shed by melanoma tumors. In: Gangliosides and Cancer, Oettgen HF (Ed.), VHC Publishers, NY, USA 207-216 (1989).
26. Nohara K, Wang F, Spiegel S. Glycosphingolipid composition of MDA-MB-231 and MCF-7 human breast cancer cell lines. Breast Cancer Res. Treat. 48, 149-157 (1998).
27. Deng W, Li R, Ladisch S. Influence of cellular ganglioside depletion on tumor formation. J. Natl. Cancer Inst. 92, 912-917 (2000).
28. Yamamura S, Handa K, Hakomori S. A dose association of GM3 with c-Scr and Rho in GM3-enriched microdomains at the B16 melanoma cell surface membrane: a preliminary note. Biochem. Biophys. Res. Commun. 236, 218-222 (1997).
29. Iwabuchi K, Handa K, Hakomori S. Separation of 'glycosphingolipid signaling domain' from caveolin-containing membrane fraction in mouse melanoma B16 cells and its role in cell adhesion coupled with signaling. J. Biol. Chem. 273, 33766-33773 (1998).
30. Chou HH, Takematsu H, Díaz S et al. A mutation in human CMP-sialic acid hydroxylase occurred after the Homo-Pan divergence. Proc. Natl Acad. Sci. USA 95, 11751-11756, 1998.
31. Irie A, Suzuki A. CMP-N-acetylneuraminic acid hydroxylase is exclusively inactive in humans. Biochem. Biophys. Res. Comun. 248, 330-333, 1998.
32. Olson MV, Varki A. Sequencing the chimpanzee genome: insights into human evolution and disease. Nat. Rev. Genet. 4, 20-28, 2003.
33. Furukawa K, Yamaguchi H, Oettgen HF, Old LJ, Lloyd KO. Analysis of the expression of N-glycolylneuraminic acid-containing gangliosides in cell and tissues using two human monoclonal antibodies. J. Biol. Chem. 263, 18507-18512 (1988).
34. Koda T, Shimosakoda T, Asaoka H et al. Detection of Hanganutziu-Deicher antigen in patients with hepatocellular carcinoma. Intern. Hepatol. Commun. 2, 310-315 (1994).
35. Vázquez AM, Alfonso M, Karlsson A et al. Generation of a murine monoclonal antibody specific for N-glycolylneuraminic acid containing gangliosides that also recognizes sulfated glycolipids. Hybridoma 14, 551-556 (1995). Describes the generation of the P3 murine monoclonal antibody which recognizes NeuGc-containing gangliosides. The P3 antibody was used to develop the 1E10 anti-idiotype antibody.
36. 1 monoclonal antibody specific for N-glycolyl GM3 ganglioside recognized breast and melanoma tumors. Hybridoma 19, 241-247 (2000).
37. Malykh YN, Schauer R, Shaw L. N-glycolylneuraminic acid in humans tumours. Biochimie 83, 623-634 (2001).
38. Marquina G, Waki H, Fernández LE et al. Gangliosides expressed in human breast cancer. Cancer Res. 56, 5165-5171 (1996).
39. Zhu A, Hurst R. Anti-N-glycolylneuraminic acid antibodies identified in healthy human serum. Xenotransplantation 9, 376-381 (2002).
40. Jerne NK. Towards a network theory of the immune system. Ann. Immunol. 125C, 373-389 (1974).
41. Alfonso M, Díaz A, Hernández AM et al. An anti-idiotype vaccine elicits a specific response to N-glycolyl sialic acid residues of glycoconjugates in melanoma patients. J. Immunol. 168, 2523-2529 (2002). Shows the use of the 1E10 anti-idiotype antibody as a vaccine in patients with advanced malignant melanoma, and demonstrates the induction of a specific immune response against NeuGc-containing gangliosides.
42. Estevez F, Carr A, Solorzano L et al. Enhancement of the immune response to poorly immunogenic gangliosides after incorporation into very small size proteoliposomes (VSSP). Vaccine 18, 190-197 (1999). Reports the immunological and physicochemical properties of very small size proteoliposomes (VSSP) obtained by using anionic detergents to incorporate gangliosides into the outer membrane protein complex of N. meningitidis.
43. Vazquez AM, Gabri MR, Hernandez AM et al. Antitumor properties of an anti-idiotypic monoclonal antibody in relation to N-glycolyl-containing gangliosides. Oncol. Rep. 7, 751-756 (2000). Reports the antitumor effects of 1E1O anti-idiotype antibody in murine models of breast cancer and melanoma.
44. Alonso DF, Gabri MR, Guthmann MD, Fainboim L, Gomez DE. A novel hydrophobized GM3 ganglioside/Neisseria meningitidis outer-membrane-protein complex vaccine induces tumor protection in B16 murine melanoma. Int. J. Oncol. 15, 59-66 (1999). Reports the antitumor effects of NAcGM3/VSSP vaccine in a preclinical model of melanoma.
45. Carr A, Mazorra Z, Alonso DF et al. A purified GM3 ganglioside conjugated vaccine induces specific, adjuvant-dependent and non-transient antitumor activity against B16 mouse melanoma in vitro and in vivo. Melanoma Res. 11, 219-227 (2001). This paper demonstrates the molecular specificity of NAcGM3/VSSP vaccine, as well as the adjuvant-dependent and non-transient character of tumor protection in the B16 melanoma model.
46. Gabri MR, Ripoll GV, Alonso DF, Gomez DE. Postoperative immunization with GM3/VSSP vaccine increased survival in B16 melanoma-bearing mice. Proc. Am. Assoc. Cancer Res. 43, 5492 (2002).
47. Gabri MR, Ripoll GV, Alonso DF, Gomez DE. Rol of cell surface GM3 ganglioside and sialic acid in the antitumor activity of a GM3-based vaccine in the murine B16 melanoma model. J. Cancer Res. Clin. Oncol. 128, 669-677 (2002).
48. Bada A, Casaco A, Arteaga M et al. Toxicity of a GM3 cancer vaccine in Macaca fascicularis monkey: a 12-month study. Hum. Exp. Toxicol. 21, 263-267 (2002).
49. Díaz A, Alfonso M, Alonso R et al. Immune responses in breast cancer patients immunized with an anti-idiotype antibody mimicking NeuGc-containing gangliosides. Clin. Immunol. 107, 80-89 (2003). Reports a Phase I clinical trial conducted in patients with Stage III/IV breast cancer who where treated with the 1E1O anti-idiotype antibody.
50. Carr A, Rodríguez E, Arango MC et al. Immunotherapy of advanced breast cancer with a heterophilic ganglioside (NGcGM3) cancer vaccine. J. Clin. Oncol. 21, 1015-1021 (2003). Reports a Phase I clinical trial performed to determine safety and immnnogenicity of the NGcGM3/VSSP vaccine in Stage III/IV breast cancer patients.
51. Kirkwood JM, Ibrahim JG, Sosman JA et al. High-dose interferon α-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB/III melanoma. Results of intergroup trial E1694/S9512/C509801. J. Clin. Oncol. 19, 2370-2380 (2001).
52. Takahashi T, Johnson TD, Nishinaka Y, Morton DL, Irie RE. IgM antiganglioside antibodies induced by melanoma cell vaccine correlate with survival of melanoma patients. J. Invest. Dermatol. 112, 205-209 (1999).
53. Center of Molecular Immunology: www.cim.sld.cu Accessed October 10, 2003.
54. Laboratory of Molecular Oncology, Quilmes National University: www.unq.edu.ar/cancer Accessed October 12, 2003.